Table 2.
Outcome | Multivariable analysis | |||||
---|---|---|---|---|---|---|
Crude analysis | Adjusted analysis | |||||
Na | Beta or OR (95% CI) | p value | Na | Beta or OR (95% CI) | p value | |
Ventilator-free days | 228 | − 4.09 (− 12.27 to 4.10) | 0.326 | 228 | − 5.91 (− 14.39 to 2.58) | 0.171 |
ICU LOS | 228 | − 1.24 (− 6.13 to 3.65) | 0.618 | 228 | − 2.85 (− 7.82 to 2.12) | 0.260 |
HLOS | 228 | − 5.32 (− 14.96 to 4.31) | 0.278 | 228 | − 8.62 (− 18.55 to 1.31) | 0.089 |
Pneumonia | 228 | 0.35 (0.14 to 0.92) | 0.033 | 228 | 0.29 (0.11 to 0.77) | 0.013 |
Motor GCS score recovery to 6 | 214 | ND | ND | 214 | ND | ND |
In-hospital mortality | 228 | 0.18 (0.02 to 1.34) | 0.093 | 228 | 0.24 (0.03 to 1.90) | 0.176 |
30-day mortality | 228 | ND | ND | 228 | ND | ND |
The multivariable analysis shows the effect of SSRF over nonoperative treatment. In the adjusted analysis, the number of fractured ribs, chest tube requirement, and presence of intracranial hypertension were entered as covariate
CI confidence interval, HLOS hospital length of stay, ICU LOS intensive care unit length of stay, mGCS motor Glasgow Coma Scale, ND not determined, OR odds ratio
Data are shown as odds ratio (OR; categorical outcome) or beta (continuous outcome) with 95% confidence interval. Bold and underlined p values are considered statistically significant. and underlined
aProvides the exact number of patients for whom data were available